youtube_live
Q3 2026 earnings • released • EPS beat +130,87% • Revenue beat +3,59%
See resultschevron_right
ALKS:NASDAQ
Alkermes Plc
45,90 USD
arrow_upward
+3,05%(+1,36) 1D
46,01 USD
arrow_upward
+0,24% (+0,11)bedtimeAfter hours
Closed: 6-ноя., 16:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALKS...
Open
44,19 USD
High
45,94 USD
Low
44,07 USD
Mkt. cap
7,71 млд
Avg. vol.
2,05 млн
Volume
1,67 млн
52-wk high
55,67 USD
52-wk low
27,00 USD
EPS
-0,01 USD
Beta
0,29
Shares outstanding
168,04 млн
No. of employees
2 миң
Open
44,19 USD
High
45,94 USD
Low
44,07 USD
Mkt. cap
7,71 млд
Avg. vol.
2,05 млн
Volume
1,67 млн
52-wk high
55,67 USD
52-wk low
27,00 USD
EPS
-0,01 USD
Beta
0,29
Shares outstanding
168,04 млн
No. of employees
2 миң
News stories
From web sources and news partners
Yahoo Finance
·
3 күн мурун
Alkermes PLC (ALKS) Q3 2026 Earnings Call Highlights: Proprietary Sales Surge 31% as Orexin ...
Yahoo Finance
·
3 күн мурун
What Alkermes (ALKS) Said on Its Q3 Earnings Call
Yahoo Finance
·
3 күн мурун
Alkermes plc Q3 2026 Earnings Call Summary
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2,05 миң
Founded1987
Headquarters-
SectorHealth Care
Industry-
Websitealkermes.com